TORONTO / Apr 16, 2024 / Business Wire / Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE) announced that the Toronto Stock Exchange (“TSX”) is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Company’s financial condition as a criterion for delisting applicable to the Company. Antibe has been invited to make submissions to TSX and a... Read More

TORONTO / Apr 09, 2024 / Business Wire / Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that its previously announced application for an Initial Order under the Companies' Creditors Arrangement Act (the " CCAA "), has been granted by the Ontario Superior Court of Justice (Commercial List) (the " Court "). Pursuant to the Initial Order, the Company has obtained protection from its... Read More

TORONTO / Apr 09, 2024 / Business Wire / Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List) (the " Court ") for an Initial Order under the Companies' Creditors Arrangement Act (the " CCAA "). The application seeks an order that would, amongst other things, stay any action by... Read More

TORONTO / Apr 01, 2024 / Business Wire / Antibe Therapeutics Inc. (“Antibe” or the “Company” TSX: ATE, OTCQX: ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration (“FDA”) that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial. Antibe expects to receive a formal Clinical Hold Letter from the FDA... Read More

The American Society of Regional Anesthesia and Pain Medicine is the largest subspecialty medical society in anesthesiology TORONTO / Mar 20, 2024 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, is pleased to announce a moderated poster presentation of data from otenaproxesul’s recent... Read More

AAPM is the primary organization for pain medicine physicians in the U.S. TORONTO / Mar 07, 2024 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, is pleased to announce a poster presentation of data from otenaproxesul’s recent pharmacokinetic/pharmacodynamic (“PK/PD”) study. The poster will be... Read More

TORONTO / Mar 04, 2024 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, today announced that the arbitrator has found in favor of Nuance Pharma in the dispute regarding the license agreement for the commercialization of otenaproxesul in the Greater China region. The confidential ruling from the... Read More

Successful PK/PD study confirms liver safety, sets stage for upgraded Phase II trial launch next month Phase II trial enhancements include placebo arm, increased sample size and adaptive design Ended quarter with $25 million in cash and equivalents TORONTO / Feb 14, 2024 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to... Read More

TORONTO / Feb 01, 2024 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is extending the Early Warrant Exercise Incentive Program (“ Early Warrant Exercise Program ”) for its 6.4 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 (“... Read More

TORONTO / Dec 29, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce an Early Warrant Exercise Incentive Program (“ Early Warrant Exercise Program ”) for its 6.5 million outstanding and unlisted share purchase warrants having an exercise price of... Read More

TORONTO / Dec 12, 2023 / Business Wire / Antibe Therapeutics Inc . (TSX: ATE, OTCQX: ATBPF) (the " Company "), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the “ Warrant Extension ”), and amending the exercise price (the “ Exercise Price Amendment ”) of the common share purchase warrants... Read More

Completed successful PK/PD study for otenaproxesul’s new formulation Phase II initiation on track for upcoming quarter Ended quarter with $28 million in cash and equivalents TORONTO / Nov 13, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its... Read More

Study delivers data required for Phase II trial, on track to initiate next quarter Confirms linear, dose-proportional pharmacokinetics Complements strong safety data already reported TORONTO / Nov 09, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is... Read More

All treatments well tolerated with no adverse safety signals No elevations in liver enzymes TORONTO / Nov 01, 2023 / Business Wire / Antibe Therapeutics Inc . (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce the completion of the pharmacokinetic/pharmacodynamic (“PK/PD”) study... Read More

Data in November will inform Phase II trial expected to launch next quarter TORONTO / Oct 18, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce the initiation of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s... Read More

TORONTO / Sep 28, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce Health Canada’s approval to initiate the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. Set to commence in... Read More

TORONTO / Sep 08, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for... Read More

TORONTO , Aug. 21, 2023 /CNW/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group. The View From The C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment.... Read More

Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024 Ended quarter with $34.3 million in cash and equivalents TORONTO / Aug 14, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target... Read More

Completed transition to otenaproxesul’s new formulation; tablet manufacturing underway PK/PD study results expected in calendar Q4 2023 with Phase II initiation in Q1 2024 Ended year with $38.9 million in cash and equivalents TORONTO / Jun 29, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to... Read More

TORONTO / Apr 25, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the Precision in Clinical Trials Summit being held in Boston on May 1 – 2, 2023. Dr. Joseph Stauffer, Antibe’s Chief Medical Officer, will deliver a live presentation... Read More

TORONTO / Apr 18, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference being held in person on April 25-26, 2023. Scott Curtis, Antibe’s Chief Operating Officer, and Dr. Joseph... Read More

TORONTO / Apr 11, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK/PD Study for Otenaproxesul’s New Formulation Further to Antibe’s update of February 15, 2023, the Company has now selected a clinical... Read More

TORONTO / Feb 15, 2023 / Business Wire / Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2022. "As we prepare for the Phase II bunionectomy trial, we're increasingly excited about the potential of... Read More